FDA Approves Voranigo for the Treatment of Grade 2 IDH-Mutant Glioma
Servier today announced the U.S. Food and Drug Administration (FDA) approved Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor
- It is indicated for the treatment of:
o adult and pediatric patients 12 years and older,
o with Grade 2 astrocytoma or oligodendroglioma,
o with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.
- Voranigo is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill. Gliomas are types of brain cancer that can hinder normal brain function and cause a variety of symptoms. Diffuse gliomas with IDH mutations represent the most common malignant primary brain tumors diagnosed in adults younger than 50 years of age.
Source: Servier
